PMID- 8423385
OWN - NLM
STAT- MEDLINE
DCOM- 19930219
LR  - 20190723
IS  - 0022-202X (Print)
IS  - 0022-202X (Linking)
VI  - 100
IP  - 1
DP  - 1993 Jan
TI  - Subacute cutaneous lupus erythematosus.
PG  - 2S-8S
AB  - Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a 
      lupus-specific eruption that identifies a unique subset of lupus erythematosus. 
      These patients were noted to have prominent photoaggravated skin disease and 
      often had musculoskeletal complaints, but generally did not develop significant 
      systemic disease. SCLE patients were later found to have other distinctive 
      features, including the frequent presence of anti-Ro antibodies, and enrichment 
      for the human histocompatibility antigens (HLA) B8 and DR3. In the 13 years of 
      published reports of SCLE patients following the initial study by Sontheimer et 
      al (Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct 
      lupus erythematosus subset. Arch Dermatol 115:1409-1415, 1979) a number of 
      additional observations regarding SCLE patients have been made. These have 
      included the recognition that SCLE may be associated with other rheumatic 
      diseases, and that photoactive medications may induce lesions of SCLE. Areas of 
      controversy concerning SCLE include conflicting studies regarding the 
      histopathology of SCLE as compared to discoid lupus erythematosus (DLE), as well 
      as the frequency of detection of anti-Ro antibodies in SCLE patients. Recent 
      interesting studies of SCLE include a description of a unique pattern of 
      immunoglobulin G (IgG) deposition on direct immunofluorescence, which may 
      indicate the binding of anti-Ro antibodies to keratinocytes in vivo.
FAU - David-Bajar, K M
AU  - David-Bajar KM
AD  - Department of Medicine, Fitzsimons Army Medical Center, Aurora, Colorado 
      80045-5001.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Invest Dermatol
JT  - The Journal of investigative dermatology
JID - 0426720
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (SS-A antibodies)
SB  - IM
MH  - Antibodies, Antinuclear/analysis
MH  - Fluorescent Antibody Technique
MH  - Hematologic Diseases/complications
MH  - Humans
MH  - Immunogenetics
MH  - Lupus Erythematosus, Cutaneous/chemically induced/drug therapy/*pathology
MH  - Rheumatic Diseases/complications
RF  - 92
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 0022-202X(93)92193-X [pii]
AID - 10.1111/1523-1747.ep12355164 [doi]
PST - ppublish
SO  - J Invest Dermatol. 1993 Jan;100(1):2S-8S. doi: 10.1111/1523-1747.ep12355164.